| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC0665 | Ap24163 | Novel inhibitor of the gatekeeper mutant of BCR-ABL, suppressing in vitro resistance |
|
| DCC0666 | Ap44mse | Potent and selective antitumor agent, effectively depleting cellular Fe, resulting in transferrin receptor-1 up-regulation, ferritin down-regulation, and increased expression of the potent metastasis suppressor, N-myc downstream regulated gene-1 |
|
| DCC0667 | Ap4a-in-1 | Novel inhibitor of the Ap4A phosphorylase (Rv2613c) of Mycobacterium tuberculosis (Mtb) |
|
| DCC0668 | Apa-apa-mpo | Novel inhibitor of PCAF bromodomain/Tat-AcK50 association |
|
| DCC0669 | Apadenoson | Selective A2a adenosine receptor agonist |
|
| DCC0670 | Apa-h-mpo | Novel inhibitor of PCAF bromodomain/Tat-AcK50 association |
|
| DCC0671 | Als-i-41 | Novel potent and selective oxytocin receptor antagonist |
|
| DCC0672 | Apj-2929 | N-Type calcium channel inhibitor |
|
| DCC0673 | Aplysamine | Histamine H3 receptor antagonist |
|
| DCC0674 | Apn Inhibitor 4cc | Potent aminopeptidase N/CD13 (APN) inhibitor |
|
| DCC0675 | Apn-in-6ab | Novel extremely potent inhibitor of APN activity in vitro, selective against other zinc-dependent enzymes such as matrix metalloproteases, and possessed limited cytotoxicity against Ad293 cells and favorable physicochemical and metabolic stability propert |
|
| DCC0676 | Apoa-i Inducer 4010b-30 | Novel inducer of endogenous ApoA-I, protecting against atherosclerotic lesion development in ApoE-/- mice, upregulating the apolipoprotein A-I gene expression, enhancing its function of promoting cholesterol efflux, ABCA1 expression and activation of PPAR |
|
| DCC0677 | Apoe4 Stabilizer | Novel apolipoprotein E4 (apoE4) stabilizer, showing activity in an IL-6 and IL-8 cytokine release assay |
|
| DCC0678 | Apogossypolone | Potent inhibitor of Bcl-2 and Mcl-1, acting as a BH3 mimetic |
|
| DCC0679 | Apomine | Inhibitor of HMG-CoA-reductase, promoting apoptosis of myeloma cells in vitro |
|
| DCC0680 | Apoptosis Inducer 5d | Novel inducer of cell death by activating apoptosis in cancer cells |
|
| DCC0681 | Apoptosis Inducer 6g | Novel anticancer agent, arresting MCF-7 cell growth at G2/M phase and S phase, dose dependent increasing in the mitochondrial membrane potential (ΔΨm) and ROS levels, decreasing in Gal-1 protein levels |
|
| DCC0682 | Apramycin Sulfate | Aminoglycoside antibiotic used in veterinary medicine |
|
| DCC0683 | Apratyramide | Marine-Derived Peptidic Stimulator of VEGF-A and Other Growth Factors with Potential Application in Wound Healing |
|
| DCC0684 | Aps5-16-2 | Novel tumor calibrated inhibitor, showing unique polypharmacology and strongly improved therapeutic index in fly and human MTC xenograft models |
|
| DCC0685 | Apsr-in-8 | First-in-class inhibitor of APS reductase (APSR), a critical enzyme in the assimilation of sulfate for the biosynthesis of cysteine and other essential sulfur-containing molecules |
|
| DCC0686 | Apx001 | Prodrug of APX-001A, the first-in-class inhibitor of the fungal protein Gwt1 |
|
| DCC0687 | Apyrabactin | Inactive analog of pyrabactin used as the negative controller |
|
| DCC0688 | Aqb007 | Selective blocker of the Aquaporin-1 ion channel conductance, slowing cancer cell migration |
|
| DCC0689 | Aqf026 | Novel agonist of the water channel aquaporin-1 (AQP1) |
|
| DCC0690 | Aqx-mn115 | Novel SH2-containing inositol 5-phosphatase (SHIP 1) modulator |
|
| DCC0691 | ar Antagonist 30 | Novel Antiandrogen, Suppressing Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth |
|
| DCC0692 | Ar Antagonist T1-12 | Novel AR antagonist, targeting the AR AF2, showing excellent AR antagonistic activity (IC 50 = 0.47 μM) and peptide displacement activity (IC 50 = 18.05 μM) |
|
| DCC0693 | Ar Protac A16 | Novel potent androgen receptor (AR) degrader, exhibiting excellent AR binding affinity (85%) and AR degradation efficacy at 30 μM |
|
| DCC0694 | Ar-12286 | Novel Rho kinase inhibitor |
|
